Navigation Links
AxoGen Appoints Peter J. Mariani Chief Financial Officer
Date:3/1/2016

AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Peter J. Mariani, as Chief Financial Officer, effective March 1, 2016. Mr. Mariani will report directly to Karen Zaderej, President and Chief Executive Officer. Greg Freitag, who has been the interim CFO since August 2015, will continue as General Counsel, Senior VP of Business Development and a member of the Board of Directors.

“Pete’s financial expertise and his broad commercial, international and operational background is a great addition to the AxoGen management team,” commented Karen Zaderej, President and Chief Executive Officer. “I am looking forward to working with him as we continue to execute on our growth strategies. I also want to thank Greg Freitag for stepping in to fill the CFO role and I am pleased he can again focus solely on our business development efforts and manage our legal requirements.”

With extensive financial, international and operational experience in the healthcare sector, Mr. Mariani will be responsible for AxoGen's global finance and administrative functions. Prior to joining AxoGen, Mr. Mariani was the Chief Financial Officer of Lensar, Inc., a privately-held global leader in next generation femtosecond laser technology for refractive cataract surgery. Prior to Lensar he served as Chief Financial Officer at Hansen Medical, Inc., a publicly-traded company that designs and manufactures medical robotics for positioning and control of catheter-based technologies. Mr. Mariani was also with Guidant Corporation, a global leader in the development and sale of medical devices for the treatment of cardiovascular disease. During his 12 years at Guidant, he held senior financial positions of increasing importance, including Vice President of Finance and Administration, Guidant Japan, and the corporate Vice President, Controller and Chief Accounting Officer. Following the sale of Guidant to Boston Scientific in 2006, Mr. Mariani co-led the global integration of the companies. He started his career at Ernst and Young, LLP, where he served a diverse client base as a Certified Public Accountant.

“I am pleased to join the AxoGen team at this important time. AxoGen’s performance over the past few years has been impressive. I am looking forward to working with Karen and the rest of the team as we continue to advance the growth strategies of these important nerve repair solutions,” commented Mr. Mariani.

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2016 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: AxoGen, Inc.

Contact:
AxoGen, Inc.
Gregory Freitag, General Counsel and SVP Business Development
386.462.6856
InvestorRelations(at)AxoGenInc(dot)com

EVC Group
Michael Polyviou/Doug Sherk – Investor Relations
212.850.6020
mpolyviou(at)evcgroup(dot)com;dsherk(at)evcgroup(dot)com

Read the full story at http://www.prweb.com/releases/2016/03/prweb13240588.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related medicine news :

1. AxoGen Inc. Reports Record Revenue Results
2. AxoGen, Inc. to Report Fourth Quarter and Full Year Results on February 29, 2016
3. AxoGen, Inc. Avance® Nerve Graft Recipient to be Honored on Donate Life Rose Parade Float
4. AxoGen Inc. Third Quarter Revenue Exceeds $8 Million
5. AxoGen, Inc. to Report Third Quarter Results on November 5, 2015
6. AxoGen, Inc. to Present at the Dawson James Securities Small Cap Growth Conference
7. AxoGen Inc.’s Avance® Nerve Graft Data Presented During Best Clinical Papers Session at the 70th Annual Meeting of the American Society for Surgery of the Hand
8. Essex Woodlands Fund IX Acquires Significant Position in AxoGen, Inc.
9. AxoGen, Inc. Expands Presence at the American Society for Surgery of the Hand (ASSH) 2015
10. Strong Operating Momentum Leads to AxoGen Inc.’s First Ever $6 Million Quarter
11. AxoGen, Inc. to Present at the Wedbush Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... its executive team as the President of its HealthBI division. McFarland will ... and contact centers. , “Scott is a utility player who balances his ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a ... When we’re born, Nature gives us a full supply of melanin – in the ... lose this natural glare-reducing pigment; however, around the age of thirty, we develop a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... the present, Mirixa Corporation recently unveiled the MirixaPro 6.0 platform. As the ... how medication management services are delivered. Based on industry research and market ...
(Date:9/19/2017)... ... September 19, 2017 , ... Back Pain Centers of ... back pain with a reputable physician in their area, announces the addition of ... as Nevada Spine Clinic was founded by board-certified spine surgeon, Jaswinder Grover, M.D. ...
(Date:9/19/2017)... ... 2017 , ... The ISO 9001 standard sets out the requirements for a ... and improve customer satisfaction. ISO 9001:2015 was released in 2015 and certified organizations have ... September 2018. , As described in this white paper , ISO ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
Breaking Medicine Technology: